Research and development

What we do

Medivir focuses on cancers of high unmet medical need, where existing therapies are not very successful and there is a great opportunity to provide real benefit to patients with few treatment options.

Who we are

Specialists in protease inhibitor design, and nucleoside- and nucleotide science. Medivir’s strategy is to apply our scientific expertise to the area of oncology to develop innovative anti-cancer drugs.

Why we do it

Cancer is the 2nd leading cause of death and more than 14 million new cases are diagnosed globally every year. This number is expected to increase in the future driven by the world’s growing and aging population.

Publications

Synergistic and additive anti-tumor effects of MIV-818 in combination with sorafenib in nonclinical hepatocellular carcinoma models

2018/04/17

Synergistic and additive anti-tumor effects of MIV-818 in combination with sorafenib in nonclinical hepatocellular carcinoma models

Presented at the annual meeting for the American Association for Cancer Research (AACR) in Chicago.

MIV-818, a nucleotide prodrug of troxacitabine-monophosphate, has been designed to target the chain-terminating nucleotide troxacitabine-triphosphate (TRX-TP) to the liver after oral dosing, while minimizing systemic exposure.
Sorafenibis a multikinaseinhibitor with antiangiogenic and antiproliferative effects that is approved for the first-line treatment of advanced hepatocellular carcinoma (HCC).
Hypoxia is induced as a result of the antiangiogenic effects of sorafenib. Since hypoxic conditions have been shown to increase cytotoxicity of TRX via increased conversion of TRX-diphosphate to TRX-TP, we investigated the effects of combining MIV-818 or TRX with sorafenibin cell lines and in xenograft mouse models of HCC.

The selective cathepsin K inhibitor MIV‑711 attenuates joint pathology in experimental animal models of osteoarthritis

2018/03/19

The selective cathepsin K inhibitor MIV‑711 attenuates joint pathology in experimental animal models of osteoarthritis

Article published in Journal of Translational Medicine 2018.

MIV-711 is a highly potent and selective cathepsin K inhibitor. The current article summarizes the therapeutic
effects of MIV-711 on joint pathology in rabbits subjected to anterior cruciate ligament transection (ACLT), and
the prophylactic effects on joint pathology in dogs subjected to partial medial meniscectomy, two surgical models of
osteoarthritis (OA).

How drug development works

Developing a new pharmaceutical is a long and resource-intensive process. It usually takes 10-15 years to bring a new drug to the shelves. Before a drug is deemed suitable for patients, it has to go through rigorous testing.